

From invention to innovation

APPLICATIONS

- Glioblastoma treatment targeting tumor initiation, progression, resistance and recurrence
- Potential treatment for other solid tumors

DEVELOPMENT PHASE

Ex vivo and *in vivo* proof of concept in several xenograft mouse models using stem-like cancer cells

Ongoing validation on other tumor mouse models, fine characterization of the compound pharmacological properties and safety evaluation

PUBLICATIONS

Galan-Moya EM et al. EMBO Rep 2011 & PLoS One 2014

INTELLECTUAL PROPERTY

PCT patent application WO2015140296 filed on 2015

CONTACT

Mail : bd-sante@idfinnov.com
Phone : +33(0)7.61.86.77.56

NEW STRATEGY FOR TARGETING CANCER STEM-LIKE CELLS


Efficient hit molecule targeting a specific cell surface receptor of stem-like cancer cells which sustain tumor initiation, progression and are also responsible for glioblastoma recurrence and poor prognosis

Glioblastoma ■ Cancer Stem-like Cells ■ CSCs ■
Cancer Recurrence ■ Peptide

PRESENTATION

Increasing evidence suggests that the systematic relapse and cancer metastasis of most solid tumors such as glioblastoma, is due to a rare population of cells within the tumor, termed cancer stem-like cells (CSCs). These cells have stem-like traits such as self-renewal capacities, are resistant to conventional chemotherapies and radiotherapies and thus operate as a niche-specific signal that sustains tumor initiation and progression. A signaling pathway that is specific to CSCs and responsible for their identity, survival and self-renewal has been recently characterized in glioblastoma.

While today no treatment specifically targets cancer-stem-like cells, **the present offer proposes a new hit molecule inhibiting a cell surface receptor of this pathway in these cells to reduce / eliminate their activity** with a high efficiency both *ex vivo* and *in vivo*.



Tumor volume evolution during a treatment with a survival pathway antagonist (Inhib.) of cancer stem-like cell in a glioblastoma xenograft mouse model © Gavard – Galan-Moya

COMPETITIVE ADVANTAGES

- First efficient treatment targeting cancer stem-like cells which are implicated in tumor initiation and therapeutic resistance
- Strong tropism for CSCs
- Mechanism of action identified
- The cell surface target is possibly also involved in other life-threatening cancers